American Society of Clinical Oncology

SHERPA: White

People

  1. Kelsen
    Kelsen
  2. Berger
    Berger
  3. Ku
    Ku
  4. Ilson
    Ilson
  5. Solit
    Solit
  6. Vakiani
    Vakiani
  7. Schultz
    Schultz
  8. Janjigian
    Janjigian
  9. Capanu
    Capanu
  10. Chou
    Chou

Groups

  1. Center for Pancreatic Cancer Research (10)
  2. Department of Medicine (10)
  3. Epidemiology and Biostatistics (10)
  4. GSK Faculty (10)
  5. Gastrointestinal Oncology Service (10)
  6. Human Oncology and Pathogenesis Program (10)
  7. Solid Tumor Oncology Division (10)
  8. Hematologic Malignancies, Division of (9)
  9. Genitourinary Oncology Service (6)
  10. Biostatistics Service (5)
Search Within
  1. "Michael Berger"
  2. "David Kelsen"
Formats
  1. Meeting Abstract (10)
Groups
  1. Center for Pancreatic Cancer Research (10)
  2. Department of Medicine (10)
  3. Epidemiology and Biostatistics (10)
  4. GSK Faculty (10)
  5. Gastrointestinal Oncology Service (10)
  6. Human Oncology and Pathogenesis Program (10)

More Groups

People
  1. David Kelsen (10)
  2. Michael Berger (10)
  3. Geoffrey Ku (9)
  4. David Ilson (8)
  5. Yelena Janjigian (8)
  6. David Solit (6)

More People

Years
  1. 2023 (1)
  2. 2019 (1)
  3. 2018 (2)
  4. 2016 (1)
  5. 2015 (3)
  6. 2014 (1)

More Years

Publications
  1. Journal of Clinical Oncology (10)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC)
    Meeting Abstract

    Keane, F.; Saadat, L.; O'Connor, C.; Chou, J. F.; Brannon, A. R.; Cowzer, D.; Crowley, F.; Debnath, N.; Bowman, A.; Xu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Park, W.; Wong, W.; Yu, K. H.; Varghese, A. M.; Riaz, N.; Balachandran, V. P.; El Dika, I. H.; Raj, N. P.; Khalil, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Detection of germline homologous recombination deficiency (HRD) in patients with metastatic esophagogastric (EG) cancer using clinical next generation sequencing (NGS)
    Meeting Abstract

    Janjigian, Y. Y.; Jonsson, P.; Kemel, Y.; Joseph, V.; Tuvy, Y.; Shameer, Z.; Ravichandran, V.; Zhang, L. Y.; Mandelker, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden (TMB) and immune- related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC)
    Meeting Abstract

    Greally, M.; Chatila, W. K.; Margolis, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Ladanyi, M.; Kelsen, D. P.; Ilson, D. H.; Berger, M. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Tuvy, Y.; Bouvier, N.; Riches, J. C.; Margolis, M.; Millang, B. M.; Scott, S. N.; Kundra, R.; Castel, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genomic profiling of esophagogastric (EG) tumors in clinical practice
    Meeting Abstract

    Riches, J. C.; Schultz, N.; Ku, G. Y.; Imtiaz, T.; Kelsen, D. P.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; Ladanyi, M.; Arcila, M. E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab
    Meeting Abstract

    Janjigian, Y. Y.; Riches, J. C.; Ku, G. Y.; Imtiaz, T.; Capanu, M.; Chou, J. F.; Kelsen, D. P.; Ilson, D. H.; Berger, M. F.; Vakiani, E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Ku, G. Y.; Ilson, D. H.; Boyar, M. S.; Capanu, M.; Chou, J. F.; Kelsen, D. P.; Imtiaz, T.; Berger, M. F.; Vakiani, E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Capanu, M.; Imtiaz, T.; Kelsen, D. P.; Ku, G. Y.; Schattner, M.; Brown, K. T.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Capanu, M.; Gromisch, C. M.; Kelsen, D. P.; Ku, G. Y.; Brown, K. T.; Schattner, M.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save